<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2043">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04357028</url>
  </required_header>
  <id_info>
    <org_study_id>N-30-2020</org_study_id>
    <nct_id>NCT04357028</nct_id>
  </id_info>
  <brief_title>Measles Vaccine in HCW</brief_title>
  <acronym>MV-COVID19</acronym>
  <official_title>Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kasr El Aini Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kasr El Aini Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Till now, mortality reports among children below 9 years remains extremely low despite that
      the incidence of death toll is high and exceeding 50,000 patients among older population, One
      speculation for lower SARS infectivity is that cross-protective antibodies against measles
      vaccine ( MV). In mice susceptible to measles virus, recombinant MV induced the highest
      titers of neutralizing antibodies and fully protected immunized animals from intranasal
      infectious challenge with SARS-CoV,

      The primary objective of the present study is to determine the benefit of measles vaccine in
      health care professional to decrease the incidence of COVID-19.

      We Hypothesized that, measles vaccine may lower the incidence of serologically proven
      SARS-CoV-2 infection and reported respiratory illness
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 13, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>COVID-19 disease incidence</measure>
    <time_frame>Time Frame: Measured over the 6 months following randomization</time_frame>
    <description>Number of participants with asymptomatic or mild COVID-19 disease defined as fever (using self-reported questionnaire), plus at least one sign or symptom of respiratory disease including cough, runny/blocked nose (using self-reported questionnaire), plus positive SARS-Cov-2 test (PCR or serology)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 pneumonia</measure>
    <time_frame>Time Frame: Measured over the 6 months following randomization</time_frame>
    <description>Number of pneumonia cases (abnormal chest X-ray) (using self-reported questionnaire and/or medical/hospital records) associated with a positive SARS-CoV-2 test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Critical care admission duration with SARS-CoV-2</measure>
    <time_frame>Time Frame: Measured over the 6 months following randomization</time_frame>
    <description>Number of days admitted to critical care (using self-reported questionnaire and/or medical/hospital records) associated with a positive SARS-CoV-2 test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen therapy with SARS-CoV-2</measure>
    <time_frame>Time Frame: Measured over the 6 months following randomization</time_frame>
    <description>Need for oxygen therapy (using self-reported questionnaire and/or medical/hospital records) associated with a positive SARS-CoV-2 test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>MMR vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 ml subcutaneous of MMR vaccine will be injected in posterior triceps aspect of upper arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.5 ml subcutaneous of saline will be injected in posterior triceps aspect of upper arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Measles-Mumps-Rubella Vaccine</intervention_name>
    <description>Measles mumps Rubella vaccine is a weak attenuated life vaccine</description>
    <arm_group_label>MMR vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>0.5 ml subcutaneous of saline will be injected in posterior triceps aspect of upper arm</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-50 years old

          -  Subjects who are willing to comply with the requirements of the study protocol and
             scheduled visits (for example, completion of the subject diary, return for follow-up
             visits) and who are willing to make themselves available for the duration of the study
             with access to a consistent means of telephone contact

        Exclusion Criteria:

          -  acute severe illness

          -  recent receipt of a blood product

          -  history of thrombocytopenia

          -  Pregnant females

          -  any chronic medical condition

          -  Any participant receiving any immune suppressive medication

          -  Immunocompromised staff

          -  Participants who have egg allergy

          -  Participants who care for immune compromised hosts

          -  Participants who test positive for COVID-19 serology prior to randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cairo University Hospital</name>
      <address>
        <city>Cairo</city>
        <zip>11559</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed M Mukhtar, M.D</last_name>
      <phone>01114208444</phone>
      <phone_ext>+2</phone_ext>
      <email>Ahmed.Mukhtar@kasralainy.edu.eg</email>
    </contact>
    <investigator>
      <last_name>Abeer Ahmed, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mostafa Alfishawy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Doaa Ghaith, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marwa Rashad, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 19, 2020</study_first_submitted>
  <study_first_submitted_qc>April 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kasr El Aini Hospital</investigator_affiliation>
    <investigator_full_name>Ahmed Mukhtar</investigator_full_name>
    <investigator_title>professor of anesthesia and intensive care</investigator_title>
  </responsible_party>
  <keyword>MMR vaccine, Respiratory failure,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Measles</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

